RONALD HUNT
CIK 1247851 · last filed 2026-02-20
RONALD HUNT is a corporate insider who has filed 51 SEC Form 4 insider transactions across 8 companies since 2012. The most recent filing, for RLYB, was dated Feb 20, 2026. Across all open-market trades the lifetime net is +$16.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $8.9M across reported positions. 28 SEC filings were submitted jointly with Philippe O. Chambon.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$8.88M
8
51
$16.44M
Filer Profile
11 MADISON AVENUE
NEW YORK, NY 10010
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RLYB | Director | 249,239 | $16.88 | $4.21M | $4.00M | 10 | 2026-02-20 |
| Iterum Therapeutics plc (ITRM) Delisted | Director | 268,244 | $0.03 | $8.0K | $8.61M | 18 | 2025-01-23 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 13,224 | $23.01 | $304.3K | $20.00M | 17 | 2024-03-11 |
| STIM | Director | 1,543,962 | $3.03 | $4.68M | $0 | 2 | 2019-04-03 |
| Lite Strategy, Inc. (MEIP) Delisted | 10%+ Owner | 0 | $3.20 | $0 | -$25.28M | 1 | 2015-03-26 |
| Relypsa Inc (RLYP) Delisted | Director | 1,924,626 | — | — | $2.05M | 1 | 2013-11-20 |
| CDE | 10%+ Owner | 0 | $20.58 | $0 | $0 | 1 | 2012-08-06 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | 3,028,439 | — | — | $7.06M | 1 | 2012-07-26 |
Recent Filings
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-20 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2025-05-15 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2025-01-23 | Iterum Therapeutics plc (ITRM) Delisted | Other (J) | — | $0 | EDGAR |
| 2025-01-06 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2024-08-12 | Iterum Therapeutics plc (ITRM) Delisted | Exer (M) | +247,934 | $0 | EDGAR |
| 2024-05-17 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2024-03-11 | Harpoon Therapeutics, Inc. (HARP) Delisted | Mixed | −1,881,969 | $0 | EDGAR |
| 2024-01-04 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2024-01-03 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +1,072 | $0 | EDGAR |
| 2023-11-28 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.